Within this body of evidence, a multicentre series of 39 patients with esophageal CD showed higher clinical response (96.8% vs. 71.4%), clinical remission (64.5% vs. 14.2%), and endoscopic response (94.7% vs. 40.0%) with anti-TNF compared with other biologics (anti-integrin/anti-IL-12/23) [50]. This evidence concerns the gene TNF and Cowden disease.